Valrubicin (val-ROO-bih-sin)A drug used to treat bladder carcinoma in situ that did not get better after treatment with bacillus Calmette-Guerin (BCG). It is used in patients who cannot have surgery right away to remove all or part of the bladder. Valrubicin is given as a solution through a catheter that is placed into the bladder. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Valrubicin is a type of anthracycline antibiotic and a type of topoisomerase inhibitor. Also called AD 32 and Valstar.
Information about Valrubicin
Valrubicin is a synthetic analogue of doxorubicin that is used to treat refractory urinary bladder cancer.
Clinical use of Valrubicin
Valrubicin has been shown to induce clinical remissions in 18% to 30% of patients. It was approved as a therapy of bladder cancer in the United States 1998, was removed in 2002 because of manufacturing issues, but reintroduced in 2009.
Dosage and administration for Valrubicin
Valrubicin is available only for intravesicular use in 5 mL single dose vials of 200 mg under the brand name Valstar. The recommended dose is 800 mg instilled in the bladder once weekly for 6 weeks.
Side effects of Valrubicin